Grand River Aseptic Manufacturing

What Grand River Aseptic Manufacturing does

Grand River Aseptic Manufacturing (GRAM) is a U.S. parenteral contract development and manufacturing organization (CDMO) headquartered in Grand Rapids, Michigan, specializing in sterile injectable fill-and-finish services for liquid and lyophilized vials, prefilled syringes, and cartridges. Founded in 2010 and majority-owned since 2017 by Arlington Capital Partners, GRAM operates across approximately 500,000 sq ft of GMP space with five manufacturing facilities, supported by SKAN isolator technology, Bausch+Ströbel VarioSys modular filling systems, groninger fill lines, IMA lyophilizers, and Stevanato automated visual inspection. Its facility-wide Contamination Control Strategy is aligned with revised EU Annex 1 guidelines, and the company has passed multiple FDA inspections with zero observations while holding European GMP certification.

GRAM serves biopharmaceutical companies, vaccine developers, and drug delivery device companies across clinical and commercial programs, with marquee relationships including Johnson & Johnson/Janssen (SARS-CoV-2 vaccine under Operation Warp Speed), Bavarian Nordic and BARDA (JYNNEOS vaccine), and strategic drug delivery partnerships with LTS LOHMANN and SHL Medical for Sorrel wearable injectors and the Maggie 5.0 autoinjector. Its GTM is direct enterprise field sales led by a VP of Business Development and a team of BD executives, supported by thought leadership content, industry events (CPHI, Pharmapack, Contract Pharma), and webinars.

Revenue is generated through fee-for-service CDMO contracts with custom quote-based pricing tied to batch size, container type, and program scope; multi-year contracts are typical. The company has scaled headcount from 25 to between 500 and 1,000 employees (sources vary), with current filling capacity of more than 50 million units per year and an additional 50 million units per year of prefilled syringe and cartridge capacity under construction as part of a $100 million investment announced in April 2026 for a fifth GMP facility targeted at Q1 2027 GMP readiness. GRAM previously appeared on the Inc. 5000 for five consecutive years (2017-2021) with 279% three-year revenue growth, and was recognized as the 2021 ISPE Facility of the Year winner for Operational Agility: COVID-19 Impact.

Name

Grand River Aseptic Manufacturing

Legal name

Grand River Aseptic Manufacturing, Inc.

Website

https://grandriverasepticmfg.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Grand River Aseptic Manufacturing (GRAM) is a U.S. parenteral CDMO providing sterile injectable fill-finish services for liquid and lyophilized vials, prefilled syringes, and cartridges to biopharmaceutical, vaccine, and drug delivery device companies. Privately held by Arlington Capital Partners, GRAM operates ~500,000 sq ft of GMP facilities in Grand Rapids, Michigan, with capacity above 50 million units per year.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (Sterile Fill-Finish CDMO)

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Lyophilization (Freeze-Drying) CDMO (HLAGABAI), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Sterile fill-finish services
• Aseptic manufacturing CDMO
• Prefilled syringe filling
• Lyophilized vial filling
• Parenteral contract manufacturing

Headquarters

HQ city

Grand Rapids

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Organization (CDMO) Services: GRAM operates as a CDMO providing sterile fill-finish contract manufacturing services for injectable drugs. Revenue is generated through fee-for-service contracts for development through commercialization services including formulation, filling, inspection, finishing, and packaging for vials, syringes, and cartridges.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Grand River Aseptic Manufacturing (GRAM) is a parenteral contract development and manufacturing organization (CDMO) providing sterile injectable fill-and-finish services. The company fills liquid and lyophilized vials, prefilled syringes, and cartridges for biologics, small molecules, and vaccines, supported by inspection, finishing, packaging, and warehousing operations, and drug delivery device partnerships.

Product overview

Grand River Aseptic Manufacturing (GRAM) operates as a contract development and manufacturing organization (CDMO) providing a unified suite of sterile injectable fill-finish services. The core offering spans three primary manufacturing capabilities: prefilled syringe and cartridge filling (supported by two dedicated filling lines), liquid and lyophilized vial filling (supported by four filling lines with isolator technology), and inspection/finishing/warehouse services. These are supported by drug delivery partnerships with SHL Medical and LTS that enable combination product capabilities for autoinjectors and on-body delivery systems. The company also employs VarioSys modular filling technology from Bausch+Ströbel as a flexible platform enabling rapid format changes between vial, syringe, and cartridge presentations within a single isolator.

Differentiator

Problem solved

Functional benefit

Products and services

• Aseptic Manufacturing Services Sterile injectable fill-and-finish contract manufacturing services for biologics, small molecules, and vaccines, covering liquid and lyophilized vials, prefilled syringes, and cartridges.
• Prefilled Syringe and Cartridge Filling Sterile filling services for prefilled syringes and cartridges, supported by two dedicated sterile filling lines with isolator technology for low to high volume production.
• Liquid and Lyophilized Vial Filling Vial filling services for both liquid and lyophilized (freeze-dried) products, supported by four vial filling lines all equipped with isolator technology.
• Inspection, Finishing, and Warehouse Quality inspection, labeling, packaging, and warehousing services for finished pharmaceutical products, including automated visual inspection systems and high-speed packaging lines.
• Drug Delivery Partnerships Strategic partnerships with drug delivery device companies offering tailored solutions for autoinjectors and on-body delivery systems for combination products.

Quantifiable outcome

• Tech transfer completed in 4 months for JYNNEOS vaccine (vs typical 12-18 months)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• groningercoreTechnology or Integration · 1 April 2026Equipment partner for the groninger 10-head fill line with capacity of 50 million units per year for prefilled syringes and cartridges. Factory Acceptance Testing (FAT) completed April 2026.
• SHL MedicalcoreStrategic or Co-development Partner · 1 September 2024Strategic partnership to offer fill-finish services for RTU cartridge used in SHL Medical's Maggie 5.0 autoinjector. Joint presentations at industry events on cartridge-based drug delivery.
• LTS LOHMANN Therapie-Systeme AG (LTS)coreStrategic or Co-development Partner · 1 August 2024Strategic alliance focused on sterile fill-finish of Sorrel wearable injector containers. GRAM has become expert on primary containers for on-body delivery systems; partnership enables large-volume cartridge filling (10mL+).
• CRBminorImplementation/ SI/ Consulting Partner · 1 October 2020Design-build partner for facility construction supporting COVID-19 vaccine manufacturing. CRB collaborated on state-of-the-art pharmaceutical manufacturing facility design.
• Johnson & Johnson (Janssen Pharmaceuticals)coreStrategic or Co-development Partner · 1 August 2020Partnership for manufacturing SARS-CoV-2 vaccine under Operation Warp Speed. GRAM supported domestic vaccine manufacturing to accelerate supply during COVID-19 pandemic.
• Kimberly ClarkminorStrategic or Co-development Partner · 1 January 2015Partnership for RightCycle program that diverted 30,357+ lbs of PPE from landfills. Program turns waste into new consumer goods supporting sustainability goals.
• SKAN AGcoreTechnology or IntegrationEquipment partner providing isolator technology across all filling lines. SKAN isolators ensure Annex 1 compliance and contamination control. Equipment used on groninger line and all existing filling equipment.
• Bausch+StröbelcoreTechnology or IntegrationEquipment partner providing VarioSys modular filling technology and high-speed vial filling lines. VarioSys allows flexible switching between vial, syringe, and cartridge formats in the same clean room.
• IMAcoreTechnology or IntegrationEquipment partner providing lyophilization (freeze-drying) technology including units with auto-loading capabilities for large-scale fill/finish facility.
• Bavarian NordiccoreStrategic or Co-development PartnerPartnership for manufacturing JYNNEOS vaccine for smallpox/monkeypox. Tech transfer completed in only 4 months with FDA inspection resulting in zero observations.
• BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development PartnerU.S. government agency partnership for vaccine manufacturing under public health emergency preparedness. Partnership enabled rapid tech transfer and manufacturing scale-up.

Scale indicators7 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• Catalent: Large, diversified CDMO offering sterile fill-finish for injectables (vials, syringes, cartridges) across biologics, vaccines, and small molecules. Direct overlap with GRAM's prefilled syringe, vial, and lyophilization capabilities, but with a broader service portfolio and global footprint.
• Baxter BioPharma Solutions: Baxter's contract manufacturing services business providing sterile fill-finish, lyophilization, and prefilled syringe capabilities for pharma and biotech customers. Overlaps directly with GRAM's vial and syringe offerings, with deeper oncology and biologics heritage.
• Patheon (Thermo Fisher Scientific): Part of Thermo Fisher's pharma services network, Patheon offers commercial-scale sterile fill-finish of vials and prefilled syringes for biologics. Comparable to GRAM on biologics fill-finish but operates within a much larger integrated CDMO platform.
• Lonza: Global CDMO leader offering mammalian biologics manufacturing integrated with sterile drug product fill-finish, including prefilled syringes and lyophilized vials. Comparable to GRAM on the fill-finish stage, with much broader upstream drug substance capabilities.
• Recipharm: European-headquartered CDMO with sterile fill-finish capabilities for injectables, including lyophilization and prefilled syringes. Comparable scope to GRAM on parenteral manufacturing, with a stronger European footprint and broader small-molecule services.
• PCI Pharma Services: Global CDMO providing sterile fill-finish of vials, prefilled syringes, and lyophilized products for clinical and commercial supply. Comparable on scope of injectable services, with stronger global network and clinical packaging capabilities.

Direct peers

• Vetter Pharma: Germany-headquartered specialist CDMO focused exclusively on sterile fill-finish of aseptically filled syringes, cartridges, and vials for biologics. Highly comparable to GRAM on scope, customer mix, and technology (isolator-based aseptic filling), though Vetter operates primarily in Europe.
• Kindeva Drug Delivery: CDMO offering sterile fill-finish and combination product manufacturing, including drug-device combination expertise. Directly overlaps GRAM's prefilled syringe and autoinjector partnership strategy; Denis Johnson's prior employer and source of leadership talent.

Emerging players

• Symbiosis Pharmaceutical Services: Scotland-based specialist CDMO focused on sterile fill-finish of vials for clinical trial and small-batch commercial biologics. Highly comparable on aseptic filling core, but smaller scale and focused on clinical/early-commercial rather than GRAM's high-volume commercial positioning.

Others

• SCHOTT Pharma: Primary packaging supplier for sterile injectables (high-quality glass vials, syringes, cartridges) and increasingly offering fill-finish services. Closely adjacent to GRAM's value chain as both a supplier of primary containers and a downstream fill-finish competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GRAsepticMfg
• Facebookfacebook.com/GrandRiverAsepticManufacturing
• LinkedInlinkedin.com/company/grand-river-aseptic-manufacturin

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grand River Aseptic Manufacturing